Investor outlets must be less and less interested in the growing number of multiple sclerosis patients who are taking Tysabri who have developed progressive multifocal leukoencephalopathy (PML).
The reason I say so is that I searched for the August announcement of new cases as reported by Biogen (and previously reported by Bloomberg News). But there was nothing to be found online. I even searched for updated information before traveling to Philly last week, but to no avail.
However, a public release of information must have taken place as the NMSS updated their website just last week with numbers reported by Biogen as of September 1, 2011. See the updated table below.
Occasionally I have received emails regarding these 'monthly' posts regarding PML cases and the accompanying table. Most of the time, readers simply thank me for giving updates.
Last month I received an email from a 'doctor' who wanted to know where the information came from. He wanted to know if I had taken the table from an official publication or even a medical journal. No, I did not reproduce this table from any other source. I have been meticulously updating this information each month as Biogen, Bloomberg, the FDA, or other official source has given their own update.
I have seen my table reproduced without permission on other websites/blogs. I was sad to see that credit was not given hence the copyright notification which has been added into the image of the chart. If you wish to reference this table, please give credit and a link. It is the proper thing to do.
And to Biogen, please don't make us wait so long for the next update. You are interferring with my methodical record keeping. :)